PURE OTC
PURE Bioscience, Inc.
1W: -11.3%
1M: +0.2%
3M: -5.2%
YTD: +59.2%
1Y: -26.0%
3Y: -37.9%
5Y: -84.7%
$0.06
-0.00 (-4.46%)
Weekly Expected Move ±25.4%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$2.2B
+112075.2% ▲
5Y CAGR: +216.7%
Gross Profit
$1.3B
+113007.6% ▲
5Y CAGR: +217.8%
Operating Income
-$2M
+27.4% ▲
Net Income
-$2M
+28.4% ▲
EPS (Diluted)
$-0.02
+28.4% ▲
EBITDA
-$2M
+31.1% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $4M | $2M | $2M | $2M | $2.2B |
| YoY Growth | -43.2% | -52.8% | +1.3% | +4.6% | +112075.2% |
| Cost of Revenue | $2M | $853K | $906K | $811K | $899M |
| Gross Profit | $2M | $1M | $971K | $1M | $1.3B |
| Gross Margin | 52.8% | 54.0% | 51.7% | 58.7% | 59.2% |
| R&D Expenses | $339K | $319K | $297K | $302K | $316M |
| SG&A Expenses | $4M | $4M | $4M | $4M | $3.3B |
| Operating Expenses | $4M | $4M | $5M | $4M | $3.6B |
| Operating Income | -$2M | -$3M | -$4M | -$3M | -$2M |
| Operating Margin | -58.8% | -184.8% | -210.1% | -159.5% | -0.1% |
| Interest Expense | $4K | $6K | $14K | $155K | $299M |
| Income Before Tax | -$2M | -$3M | -$4M | -$3M | -$2M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$2M | -$3M | -$4M | -$3M | -$2M |
| Net Margin | -59.1% | -188.7% | -211.0% | -170.7% | -0.1% |
| EPS (Diluted) | $-0.03 | $-0.04 | $-0.04 | $-0.03 | $-0.02 |
| EBITDA | -$2M | -$3M | -$4M | -$3M | -$2M |
| Shares Outstanding | 87M | 89M | 111M | 112M | 112M |